Archive

HIGHLIGHTS

 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP’s portfolio company Xeltis raises a substantial new round
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical-[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP FUNDRAISING NEWS
LSP announces EUR 250 mln final closing of LSP 5
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

2018


BioCapital Europe 2018, organised by LSP
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li [...]
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis
FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will [...]
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop an [...]
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -   UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a c [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP’s portfolio company Xeltis raises a substantial new round
Amsterdam, the Netherlands, November 16, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces that its portfolio company Xeltis has raised a substantial new round. The clinical-[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
LSP FUNDRAISING NEWS
LSP announces EUR 250 mln final closing of LSP 5
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

$smarty.now|date_format:"%Y"


BioCapital Europe 2018, organised by LSP
BioCapital Europe 2018, an LSP (Life Sciences Partners) event, is delighted to announce its 16th consecutive event, taking place on 6th February 2018 in Amsterdam, The Netherlands. BioCapital Europe is Europe’s prem [...]
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li [...]
FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis
FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will [...]
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop an [...]
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -   UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a c [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview